STOCK TITAN

Fortress Biotech (FBIO) SEC Filings, Oct-Nov 2025

FBIO NASDAQ

Fortress Biotech, Inc. filings document a biopharmaceutical issuer with common stock and 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock listed on the Nasdaq Capital Market. Its SEC record includes Form 8-K reports on operating results, FDA approvals, priority review voucher monetization, credit agreement amendments and subsidiary capital actions.

Proxy materials describe annual meeting matters, board governance, executive compensation and equity awards. Registration statements and material-event filings add disclosure on securities offerings, capital structure, risk factors, material agreements and ownership interests in portfolio companies such as Cyprium Therapeutics and Journey Medical.

Form 8-K
Rhea-AI Summary

Fortress Biotech (FBIO) furnished an 8-K announcing it issued a press release with a corporate update and financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.

The company stated the information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings unless specifically referenced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
current report
-
Rhea-AI Summary

David Jin, Chief Financial Officer of Fortress Biotech, Inc. (FBIO), reported an acquisition of 2,711 common shares on 10/01/2025 under the company's Employee Stock Purchase Plan at a price of $1.309 per share. The filing states the purchase was exempt under Rule 16b-3(c) and 16b-3(d). After the transaction, Mr. Jin beneficially owns 1,248,604 shares, which the filer says include 1,230,000 shares underlying deferred restricted stock units. The Form 4 is signed and dated 10/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
insider
-
Rhea-AI Summary

Fortress Biotech, Inc. (reporting person) reported a Section 16 filing related to Mustang Bio, Inc. (MBIO). On 09/29/2025 the reporting person received 59,334 shares of Mustang Bio common stock at a reported price of $0, increasing its beneficial ownership to 258,192 shares. The filing states these shares were granted under an agreement that awards the reporting person equity equal to 2.5% of the gross proceeds of any debt or equity financing; the grant followed the issuer’s receipt of proceeds from the exercise of previously issued warrants. The Form 4 is signed by an attorney-in-fact for the reporting person on 10/01/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
insider
Rhea-AI Summary

Fortress Biotech, Inc. reported that the U.S. Food and Drug Administration has issued a complete response letter for CUTX-101 (copper histidinate). A complete response letter generally means the FDA has finished reviewing an application but cannot approve it in its present form. Fortress disclosed this development through a press release dated October 1, 2025, which is attached as an exhibit to the report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.72%
Tags
current report

FAQ

How many Fortress Biotech (FBIO) SEC filings are available on StockTitan?

StockTitan tracks 34 SEC filings for Fortress Biotech (FBIO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Fortress Biotech (FBIO)?

The most recent SEC filing for Fortress Biotech (FBIO) was filed on November 13, 2026.